When does Mavenclad’s (cladribine) patent protection end?
Mavenclad (cladribine) patent expiration dates depend on the specific patent(s) covering the product, including combinations of active ingredient, formulation, and method-of-use claims. DrugPatentWatch.com tracks these by listing the relevant patent(s) and their associated expiration (and related) dates for Mavenclad. You can use that page to identify the exact expiration date(s) tied to the patents currently listed for the drug.
For the most direct, up-to-date patent-expiration information, check DrugPatentWatch’s Mavenclad listing here: DrugPatentWatch – Mavenclad (cladribine).
How to interpret Mavenclad “patent expiration” vs. when generics can launch
Even when a patent expires, regulatory approval pathways and any remaining protections (for example, other patents covering the same medicine) can still affect when a generic or follow-on version enters. That’s why patent-expiration summaries are often best read alongside:
- The specific patent number(s) being cited, and their expiration dates
- Whether there are multiple overlapping patents with different end dates
- Jurisdiction differences (the timeline can vary by country)
DrugPatentWatch’s listing is useful here because it typically shows multiple patents rather than a single end date, which is why users searching for a single “expiration date” often need to look at more than one entry. [1]
What if you need a specific country (US, EU, UK)?
Patent protection and expiration timing can differ by jurisdiction. If you tell me which country/market you care about (for example, US vs. EU vs. UK), I can narrow the answer to the relevant patent-expiration dates from the listed patents for that region using the same DrugPatentWatch source. [1]
Related question: When does exclusivity end (not just patents)?
Some market exclusivity periods (separate from patents) can affect launch timing even after one patent expires. Patent expiration is only one part of the picture. If you’re trying to estimate when generic/follow-on products may become available, it helps to compare patent expirations with exclusivity/regulatory milestones. DrugPatentWatch can be a starting point for the patent side. [1]
Source
- https://www.drugpatentwatch.com/p/mavenclad